Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trialK.N. Chi, Eleni Efstathiou, Gerhardt Attard et al.|Annals of Oncology|2023Cited by 195
Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapyAlexander W. Wyatt, K.N. Chi, Gillian Vandekerkhove et al.|Annals of Oncology|2016Cited by 6